# Pizarra — PT-pseudo_0bd72f429a8b (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0bd72f429a8b
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 56-year-old male
  - PSA: 5.3 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.1 ng/mL²
  - PSA velocity: 2.26 ng/mL/yr
  - Prior PSA: 2.7 ng/mL
  - Prostate volume: 48.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.40281674 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30)
  - Problem list / PMHx: Obesity (BMI >30)
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.3 ng/mL. PI-RADS 4. PSAD 0.10. Prostate volume 48 mL. DRE nodus. csPCa 0.40.

Vitals: weight 79 kg, height 175 cm, BMI 25.8, BP 123/64 mmHg, HR 80 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2021).

Chief complaint: Request for clinical re-evaluation driven by previous biopsy results and a current PSA elevation to 5.3 ng/mL.

History: A 56-year-old retired bank clerk first entered investigation during early 2023 after a PSA elevation triggered a positive biopsy and subsequent monitoring protocol. He is married and shares his residence with his partner, maintaining a fairly active routine that includes cycling roughly 20 kilometres twice weekly. Lower urinary tract symptoms register at a moderate IPSS of 11, with no reports of pelvic pain or haematuria. After accumulating 33 pack-years of smoking, he ceased tobacco use in 2021. Alcohol intake stays near one unit per week. Unrelated urological issues include uncomplicated cataract surgery performed three years prior and routine podiatry visits. He previously opted out of research trials and currently maintains a BMI exceeding 30 without any active medications.

Physical examination: DRE — texture: moderately enlarged gland with a distinct Nodus palpable in the left peripheral zone; mobility: unrestricted. General assessment shows stable vital signs, absent lymphadenopathy, and no bone tenderness.

Patient info: retired bank clerk; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 1 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 11/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.50 +/- 0.18   (95% CI 0.15-0.85)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.18  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against the earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value of 5.3 ng/mL?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current PSA/imaging findings, warrants a re-biopsy or deferral, as the initial panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical model only weighed the structured panel, failing to incorporate the context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer" to "is the existing lesion stable or progressed." Specifically, the prior positive biopsy status is a critical piece of information that the model did not weigh against the current PI-RADS 4 score and rising PSA velocity (2.26 ng/mL/yr).

WHY THE SUGGESTION COULD BE WRONG
The prior positive biopsy result suggests that the decision is not a simple initial screening, but a risk stratification of progression. The prior positive result, combined with a current PI-RADS 4 score and rising PSA, could lead to a false negative if the model defaults to 'NO BIOPSY' based on the initial panel. The model's suggestion of NO BIOPSY (p=0.50) is in the 'discuss' tier, meaning the panel is genuinely insufficient, and the model cannot distinguish between a biopsy and deferral based on the visible data alone.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against the earlier study?
psa_trend - What is the serial PSA trend beyond the headline value of 5.3 ng/mL?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
Guidelines indicate that the decision depends on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Amsterdam UMC (VUmc) | Multiparametric MRI Prostate | 10 Jan 2025
The report notes a PI-RADS 4 lesion in the left peripheral zone, base/mid, measuring 14 x 12 x 10 mm. It does not explicitly compare this finding to a previous MRI, only noting the current status.

get_psa_trend
The serial PSA trend shows values: Jan 2023: 3.5 ng/mL, Jan 2024: 3.5 ng/mL, Jan 2025: 5.3 ng/mL. This indicates a rising trend, with a significant jump between 2024 and 2025.

get_previous_notes
The prior biopsy confirmed low-risk prostate cancer. The patient was on an active surveillance protocol with quarterly PSA checks and annual MRI evaluations. The notes indicate a PSA increase to 2.7 ng/mL in Jan 2024, which prompted plans for a repeat MRI that were postponed.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- Rising PSA trend: 3.5 ng/mL (Jan 2023) to 5.3 ng/mL (Jan 2025), with a velocity of 2.26 ng/mL/yr.
- Current imaging finding: PI-RADS 4 lesion in the left peripheral zone.
- Patient is on an active surveillance protocol, and the current PSA elevation warrants re-evaluation.

AGAINST sampling this patient now:
- Prior biopsy result: Low-risk prostate cancer (ISUP grade not specified).
- No explicit documentation in the retrieved notes regarding the prior biopsy grade or a specific plan for re-biopsy.

WHERE THIS LEANS
The evidence points towards a need for further investigation due to the rising PSA and the PI-RADS 4 finding in the context of prior surveillance. The decision is not definitively settled but leans towards re-evaluation/biopsy given the clinical context.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a rising PSA trend and a PI-RADS 4 finding within an active surveillance context, supports a leaning towards re-evaluation/biopsy, settling the ambiguity left by the initial panel.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical model only weighed the structured panel, failing to incorporate the context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer" to "is the existing lesion stable or progressed." Specifically, the prior positive biopsy status is a critical piece of information that the model did not weigh against the current PI-RADS 4 score and rising PSA velocity (2.26 ng/mL/yr).

WHY THE SUGGESTION COULD BE WRONG
The prior positive biopsy result suggests that the decision is not a simple initial screening, but a risk stratification of progression. The prior positive result, combined with a current PI-RADS 4 score and rising PSA, could lead to a false negative if the model defaults to 'NO BIOPSY' based on the initial panel. The model's suggestion of NO BIOPSY (p=0.50) is in the 'discuss' tier, meaning the panel is genuinely insufficient, and the model cannot distinguish between a biopsy and deferral based on the visible data alone.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against the earlier study?
psa_trend - What is the serial PSA trend beyond the headline value of 5.3 ng/mL?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
Guidelines indicate that the decision depends on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Amsterdam UMC (VUmc) | Multiparametric MRI Prostate | 10 Jan 2025
The report notes a PI-RADS 4 lesion in the left peripheral zone, base/mid, measuring 14 x 12 x 10 mm. It does not explicitly compare this finding to a previous MRI, only noting the current status.

get_psa_trend
The serial PSA trend shows values: Jan 2023: 3.5 ng/mL, Jan 2024: 3.5 ng/mL, Jan 2025: 5.3 ng/mL. This indicates a rising trend, with a significant jump between 2024 and 2025.

get_previous_notes
The prior biopsy confirmed low-risk prostate cancer. The patient was on an active surveillance protocol with quarterly PSA checks and annual MRI evaluations. The notes indicate a PSA increase to 2.7 ng/mL in Jan 2024, which prompted plans for a repeat MRI that were postponed.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- Rising PSA trend: 3.5 ng/mL (Jan 2023) to 5.3 ng/mL (Jan 2025), with a velocity of 2.26 ng/mL/yr.
- Current imaging finding: PI-RADS 4 lesion in the left peripheral zone.
- Patient is on an active surveillance protocol, and the current PSA elevation warrants re-evaluation.

AGAINST sampling this patient now:
- Prior biopsy result: Low-risk prostate cancer (ISUP grade not specified).
- No explicit documentation in the retrieved notes regarding the prior biopsy grade or a specific plan for re-biopsy.

WHERE THIS LEANS
The evidence points towards a need for further investigation due to the rising PSA and the PI-RADS 4 finding in the context of prior surveillance. The decision is not definitively settled but leans towards re-evaluation/biopsy given the clinical context.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fulfilled, and the retrieved evidence points towards a leaning towards biopsy due to rising PSA and current PI-RADS 4 finding within an active surveillance context, despite the lack of explicit prior grade documentation.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The statistical prior suggested no biopsy, but the retrieved evidence pointed towards sampling due to the rising PSA trend (3.5 to 5.3 ng/mL) and the PI-RADS 4 finding within an active surveillance protocol. This conflicted with the guideline criterion which abstained because the prior biopsy grade was not documented. The evidence leaning towards biopsy was supported by the rising PSA and imaging findings, overturning the statistical prior's suggestion by incorporating the context of progression.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
